Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2010

View Archived Issues

IBAT inhibitor A-3309 improves constipation in double-blind trial

Menveo protects adults age 56 years and older from meningococcal disease

Promising preclinical profile of MEK kinase inhibitor TAK-733

Myriad's candidate anticancer therapeutics inhibit Nampt

Bayer and AstraZeneca claim new glucocorticoid receptor ligands

Roche discloses new hepatitis C virus NS5B polymerase inhibitors

New compounds potentiating the activity of mutant glucosidades

Vertex claims new CFTR channel modulators

JAK2 inhibitor TG-AZ1 sensitizes lung cancer cells to radiation

Odanacatib promising in phase II trial in postmenopausal women with low BMD

Early indomethacin reduces early atrial fibrillation recurrence after AF ablation

Brinavess superior to amiodarone for treating atrial fibrillation in phase III trial

Biogen Idec claims new lysophospholipid S1P1 receptor agonists

Roche and Biogen Idec discontinue ocrelizumab development in RA

Kyowa Hakko Kirin announces highlights of first quarter 2010

FDA approves Stealth Peptides' IND for phase I Bendavia trial

Vernalis issues management statement

Lentigen receives NIH grant for gene therapy research in Hunter's syndrome

NicOx discusses activities in strategic update

FDA grants priority review to Sigma-Tau's NDA for cysteamine eye drops

Idebenone misses primary endpoint in phase III trial in Friedreich's ataxia

FDA approves Zymaxid ophthalmic solution 0.5% for bacterial conjunctivitis

Oncolytics Biotech to begin phase I ReoT3D trial in colorectal cancer

NanoViricides and UCSF collaborate to test anti-HIV drug candidates

U.K. and Spanish regulators recommend Sativex for approval

Health Canada grants Centocor marketing authorization for Yondelis in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...